Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke

Prior treatment

• Allergic to tetracycline antibiotics or any component of the investigational drug.
• Took tetracycline antibiotics within previous one week.
• History of intracranial hemorrhagic diseases within previous 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/external hematoma, etc.
• Received any of the following treatments within previous 3 months: systemic retinoic acid, androgen/antiandrogen therapy (e.g., anabolic steroids, andiolactone).
• History of intracranial or spinal surgery within previous 3 months; History of therapeutical surgery or major physical trauma within previous 1 month.
• Participated in other interventional clinical trials within previous 3 months.

Other illness

• History of pseudomembranous colitis or antibiotic-related colitis.
• Known community-acquired bacterial infection, such as pneumonia or urinary tract infection.
• Other conditions that are not suitable for participating in this clinical trial, such as inability to understand and/or follow the research procedures due to mental, cognitive, emotional, or physical disorders, etc.

Lab values

• Severe hepatic insufficiency, renal insufficiency or receiving dialysis before randomization for various reasons (Severe hepatic insufficiency was defined as ALT \>3 times the upper limit of normal value or AST \>3 times the upper limit of normal value; Severe renal insufficiency was defined as creatinine \> 3.0 mg/dl \[265.2 μmol/L\] or glomerular filtration rate\<30 ml/min/1.73m2).
• Bleeding tendency (including but not limited to): platelet count \<100×109/L; Administration of oral warfarin and INR\>2; Administration of heparin within previous 48 hours and APTT≥35s; Hereditary bleeding disorders, such as hemophilia.

Age

• Women of childbearing age who do not use effective contraception and have no negative pregnancy test records; Women during lactation and pregnancy.

Other

• Known to be resistant to other tetracyclines.
• Intracranial tumors, vascular malformations and other intracranial space-occupying lesions.
• Rare or unknown etiology of LVO, such as dissection and vasculitis.
• Life expectancy of less than 6 months due to advanced stage of comorbidity.

• 18≤Age≤80 years old;
• Patients with acute ischemic stroke confirmed by CT or MRI within 72 hours of onset;
• 4≤NIHSS≤25, and Ia≤1;
• First stroke or mRS 0-1 before the onset of current stroke;
• Patients or his/her legal representatives are able to understand and sign the informed consent.